[go: up one dir, main page]

Ikenoue et al., 2020 - Google Patents

A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease

Ikenoue et al., 2020

View HTML
Document ID
7239978890622443025
Author
Ikenoue T
Aprile F
Sormanni P
Ruggeri F
Perni M
Heller G
Haas C
Middel C
Limbocker R
Mannini B
Michaels T
Knowles T
Dobson C
Vendruscolo M
Publication year
Publication venue
Scientific reports

External Links

Snippet

Bicyclic peptides have great therapeutic potential since they can bridge the gap between small molecules and antibodies by combining a low molecular weight of about 2 kDa with an antibody-like binding specificity. Here we apply a recently developed in silico rational design …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Similar Documents

Publication Publication Date Title
Ikenoue et al. A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer’s disease
Ukmar-Godec et al. Lysine/RNA-interactions drive and regulate biomolecular condensation
Stains et al. Molecules that target beta‐amyloid
Mok et al. Mapping interactions with the chaperone network reveals factors that protect against tau aggregation
Groveman et al. Parallel in-register intermolecular β-sheet architectures for prion-seeded prion protein (PrP) amyloids
Xu et al. Tuning the rate of aggregation of hIAPP into amyloid using small-molecule modulators of assembly
Wilbur et al. Actin binding by Hip1 (huntingtin-interacting protein 1) and Hip1R (Hip1-related protein) is regulated by clathrin light chain
Stoppini et al. Systemic amyloidosis: lessons from β2-microglobulin
Wallin et al. The neuronal tau protein blocks in vitro fibrillation of the amyloid-β (Aβ) peptide at the oligomeric stage
Murakami et al. Neurotoxicity and physicochemical properties of Aβ mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease
KR20130045850A (en) Oligomer-specific amyloid beta epitope and antibodies
Hervás et al. Divergent CPEB prion-like domains reveal different assembly mechanisms for a generic amyloid-like fold
Rintala-Dempsey et al. Insights into S100 target specificity examined by a new interaction between S100A11 and annexin A2
Samson et al. Emerin self‐assembly mechanism: role of the LEM domain
Seetaloo et al. Millisecond hydrogen/deuterium-exchange mass spectrometry approach to correlate local structure and aggregation in α-synuclein
Landrieu et al. Deciphering the structure and formation of amyloids in neurodegenerative diseases with chemical biology tools
Habashi et al. Aza-Residue Modulation of Cyclic d, l-α-Peptide Nanotube Assembly with Enhanced Anti-Amyloidogenic Activity
EP3400445B1 (en) Method of identifying novel protein aggregation inhibitors based on chemical kinetics
Wafer et al. Thermodynamic and kinetic analysis of peptides derived from CapZ, NDR, p53, HDM2, and HDM4 binding to human S100B
Lindgren et al. N‐terminal engineering of amyloid‐β‐binding Affibody molecules yields improved chemical synthesis and higher binding affinity
Beyer et al. Solid‐Phase Synthesis and Characterization of N‐Terminally Elongated Aβ− 3–x‐Peptides
Ikenoue et al. Rationally designed bicyclic peptides prevent the conversion of Aβ42 assemblies into fibrillar structures
EP3153520A1 (en) Peptide tags for marking proteins by fusion, and antibodies for the detection thereof
US10100082B2 (en) Hexapeptide for neuroprotection against a β toxicity
Drombosky et al. Native tau structure is disrupted by disease-associated mutations that promote aggregation